• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CVBT Comments That Imaging Modalities Being Developed By Philips Medical Systems Have Direct Application to the Diagnosis and Treatment of Diseases CVBT is Targeting With Cardio Vascu-Grow(TM)

Posted on: Friday, 24 February 2006, 12:00 CST

CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT.OB) announced today that a lecture delivered at the International Regenerative Medicine Foundation's 3rd annual conference held in Kauai, Hawaii has important implications for the development of its lead drug candidate, Cardio Vascu-Grow(TM). During that lecture, Dr. David Rollo, Chief Medical Officer of Philips Medical Systems, a company that develops, manufactures and markets advanced imaging equipment ("Philips"), spoke on the application of diagnostic imaging to assess the efficacy of FGF-1 for the diagnosis, treatment and management of ischemia. FGF-1 is the protein component of Cardio Vascu-Grow(TM).

Dr. Rollo's talk focused on Philips' recent development of imaging devices and related software that image molecular agents designed to specifically visualize, at high sensitivity, ischemic areas of the heart, brain and other tissues. Ischemia is poor blood perfusion due to blocked arteries. Dr. Rollo indicated that, as FGF-1 is a potent inducer of new blood vessel growth, new imaging agents could be utilized to first diagnose ischemic diseases then assess the effect of FGF-1 given to those patients. CVBT currently has two FDA-allowed clinical trials to treat ischemic diseases; the first in no-option heart patients; the second in ischemic leg disease, which leads to dermal ulcers that do not heal. A third trial in peripheral vascular disease is scheduled to start later this year.

CVBT's Chief Executive Officer, Daniel Montano stated, "We were very interested in Dr. Rollo's lecture and hear his belief that molecular imaging techniques Philips is developing in collaboration with drug discovery groups could have direct application to the diagnosis and treatment of many of the diseases we have targeted for treatment with Cardio Vascu-Grow(TM). We feel very strongly that newer imaging modalities will be crucial to the proper diagnosis and management of this large class of patients who suffer from poor blood perfusion and ischemic diseases. It is our hope that we will be able to add this exciting new imaging technology to our ongoing clinical studies at some point in the future. We believe molecular imaging will not only dramatically simplify measuring the effect of Cardio Vascu-Grow(TM) in ischemic tissues, but will be very important in helping us select the proper patients for our clinical trails who are most likely to benefit from our treatment."

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding our future revenues, cash usage, our cash flow breakeven point, and our future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of Cardio Vascu-Grow(TM), market acceptance of CardioVascular BioTherapeutics, Inc. products by our customers, new developments in the industry, future revenues, future expenses, future margins, cash usage, and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc.

Source: Business Wire

More News in this Category